Human leukocyte antigen-G upregulates immunoglobulin-like transcripts and corrects dysfunction of immune cells in immune thrombocytopenia

Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I antigen with potent immune-inhibitory function. HLA-G benefit patients in allotransplantation and autoimmune diseases by interacting with its receptors, immunoglobulin-like transcripts. Here we observed significantly less HLA-G in plasma from immune thrombocytopenia (ITP) patients positive for anti-platelet autoantibodies compared with autoantibodies-negative patients or healthy controls, while we found that HLA-G is positively correlated with platelet counts in both patients and healthy controls. We also found less membrane bound HLA-G and immunoglobulin-like transcripts on CD4(+) and CD14(+) cells in patients. Recombinant HLA-G upregulated immunoglobulin-like transcript 2 expression on CD4(+) and immunoglobulin-like transcript 4 on CD14(+) cells. HLA-G upregulated IL-4 and IL-10, and downregulated tumor necrosis factor-alpha, IL-12 and IL-17 secreted by patient peripheral blood mononuclear cells, suggesting a stimulation of Th2 differentiation and downregulation of Th1 and Th17 immune response. HLA-G-modulated dendritic cells from ITP patients showed decreased expression of CD80 and CD86, and suppressed CD4(+) T-cell proliferation compared to unmodulated cells. Moreover, HLA-G-modulated cells from patients induced less platelet apoptosis. HLA-G administration also significantly alleviated thrombocytopenia in a murine model of ITP. In conclusion, our data demonstrated that impaired expression of HLA-G and immunoglobulin-like transcripts is involved in the pathogenesis of ITP; recombinant HLA-G can correct this abnormality via upregulation of immunoglobulin-like transcripts, indicating that HLA-G can be a diagnostic marker and a therapeutic option for ITP.

Automated summary

The expression of HLA-G and immunoglobulin-like transcripts is found to be impaired in patients with ITP. Recombinant HLA-G can correct this abnormality by upregulating immunoglobulin-like transcripts, stimulating Th2 differentiation, and downregulating Th1 and Th17 immune responses, suggesting that HLA-G can be a potential diagnostic marker and therapeutic option for ITP.